Targets › TYMS
74 programs from 59 companies in 88 trials: 56 Phase 2, 20 Phase 3, 11 Phase 1, 1 Phase 4; Oncology, Other; next expected readout Nov 2026.
Catalyzes the reductive methylation of 2'-deoxyuridine 5'-monophosphate (dUMP) to thymidine 5'-monophosphate (dTMP), using the cosubstrate, 5,10- methylenetetrahydrofolate (CH2H4folate) as a 1-carbon donor and reductant and contributes to the mitochondrial and nuclear de novo thymidylate biosynthesis pathway. (UniProt, P04818)
Open in Phaseline: the race on TYMS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Duke University | Floxuridine Thymidylate synthase inhibitor | TYMS | Phase 4 | Pancreatic Ductal Adenocarcinoma | Dec 2028 |
| Assistance Publique - Hôpitaux de Paris | Modified FOLFIRINOX Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit | TOPO1, TOPO2A, MTHFR, TYMS | Phase 3 | Rectal Cancer | Dec 2026 |
| Kyungpook National University Hospital | FOLFOX-6 Combination chemotherapy: oxaliplatin (platinum agent), leucovorin (reduced folate), and 5 | DPYD, TYMS, DHFR | Phase 3 | Colon Cancer | Dec 2026 |
| Institut de Recherches Internationales Servier | Trifluridine/tipiracil hydrochloride (S95005) Thymidylate synthase inhibitor; trifluridine is an antimetabolite that inhibits thymidylat | TYMS | Phase 3 | Metastatic Colorectal Cancer | Dec 2026 |
| Centre Hospitalier Universitaire Dijon | modified FOLFOX Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor | TOPO2, TYMS, DHFR, SLC22A16 | Phase 3 | Colon Cancer; Locally Advanced or Metastatic Small Bowel Adenocarcinoma | Feb 2027 |
| Shandong Cancer Hospital and Institute | TAS-102 Trifluridine/tipiracil - nucleoside analogue with thymidine phosphorylase inhibitor | TYMS | Phase 3 | Rectal Cancer | Jun 2027 |
| First Affiliated Hospital, Sun Yat-Sen University | Induction Chemotherapy (TPF regimen) Docetaxel, cisplatin, and 5-fluorouracil combination | Tubulin, TP53, TYMS, RRM1 | Phase 3 | Locally Advanced Nasopharyngeal Carcinoma | Aug 2027 |
| Seoul National University Hospital | mFOLFIRINOX (preoperative) Multi-agent chemotherapy combining irinotecan (topoisomerase I inhibitor), fluorouracil (t | TOPO1, DHFR, TYMS | Phase 3 | Resectable Pancreatic Cancer | Dec 2027 |
| Chinese University of Hong Kong | FLOT Combination chemotherapy: 5-fluorouracil (5-FU) inhibits thymidylate synthase; Leucovorin | TYMS | Phase 3 | Cancer of Stomach, Adenocarcinoma | Dec 2027 |
| Chinese University of Hong Kong | XELOX Combination chemotherapy: Capecitabine (oral 5-FU prodrug) inhibits thymidylate synthase; | TYMS | Phase 3 | Cancer of Stomach, Adenocarcinoma | Dec 2027 |
| Fudan University | XELOX adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent) and capecitabine (5-fluorouracil pr | DHFR, TYMS, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Fudan University | mFOLFIRINOX adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi | DHFR, TYMS, TOPO1, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Fudan University | mFOLFOX6 adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent), leucovorin (folinic acid), and 5-f | DHFR, TYMS, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Sun Yat-sen University | XELOX Oxaliplatin (platinum agent) combined with capecitabine (prodrug of 5-fluorouracil/TYMS in | TYMS | Phase 3 | Rectal Cancer | Sep 2028 |
| Kyungpook National University Hospital | FOLFOX Combination chemotherapy: 5-fluorouracil + leucovorin + oxaliplatin | DHFR, TYMS | Phase 3 | Colon Cancer | Dec 2028 |
| ECOG-ACRIN Cancer Research Group | Floxuridine Thymidylate synthase inhibitor | TYMS | Phase 3 | Metastatic Colorectal Carcinoma | Jun 2029 |
| Zhejiang Cancer Hospital | 5-FU monotherapy DNA-damaging chemotherapy; inhibits thymidylate synthase | TYMS | Phase 3 | Colon Cancer | Dec 2029 |
| The Netherlands Cancer Institute | Floxuridine Thymidylate synthase inhibitor | TYMS | Phase 3 | Colorectal Neoplasms | Jan 2030 |
| Sixth Affiliated Hospital, Sun Yat-sen University | CapeOx chemotherapy regimen Capecitabine/oxaliplatin combination chemotherapy | TYMS, DHFR | Phase 3 | Colorectal Cancer | Feb 2031 |
| Sixth Affiliated Hospital, Sun Yat-sen University | FOLFOX chemotherapy regimen 5-FU/leucovorin/oxaliplatin combination chemotherapy | TYMS, DHFR | Phase 3 | Colorectal Cancer | Feb 2031 |
| Centre Hospitalier Universitaire Dijon | Trifluridine tipiracil Thymidylate synthase inhibitor (trifluridine) with thymidine phosphorylase inhibitor (tipi | TYMS | Phase 3 | Colon or Upper Rectum Adenocarcinoma | May 2032 |
| LIN YANG | trifluridine/tipiracil (TAS-102) Thymidylate synthase inhibitor; prodrug converted to active metabolite | TYMS | Phase 2 | Gastric Cancer Adenocarcinoma Metastatic | Nov 2026 |
| Henan Cancer Hospital | TAS-102 Thymidylate synthase inhibitor (prodrug: trifluridine and tipiracil combination) | TYMS | Phase 2 | Colorectal Cancer | Nov 2026 |
| Peking Union Medical College Hospital | XELOX regimen Capecitabine + oxaliplatin combination chemotherapy | TYMS | Phase 2 | Locally Advanced Rectal Adenocarcinoma | Dec 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | S-1 Fluorouracil prodrug; inhibits thymidylate synthase and orotate phosphoribosyltransferase | TYMS, OPRT | Phase 2 | Biliary Tract Cancer; Pancreatic Adenocarcinoma; Intrahepatic Cholangiocarcinoma (Icc); Neuroendocrine Tumors | Dec 2026 |
| Qilu Hospital of Shandong University | S-1 Fluoropyrimidine antimetabolite (tegafur, gimeracil, oteracil potassium) | TYMS | Phase 2 | HER2-positive Gastric Cancer | Dec 2026 |
| Ruijin Hospital | S-1 Oral fluoropyrimidine (tegafur/5-FU/gimeracil/oteracil combination) | TYMS, DHFR | Phase 2 | Pancreatic Neoplasms; Gastric or Esophagogastric Junction Adenocarcinoma | Dec 2026 |
| Rutgers, The State University of New Jersey | sFOLFOXIRI (alternating FOLFOX and FOLFIRI) Fluorouracil-based chemotherapy combining FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) | DHFR, TYMS, TOPO1 | Phase 2 | Gastro-Intestinal Cancer | Feb 2027 |
| Taichung Veterans General Hospital | NALIRIFOX Liposomal irinotecan (topoisomerase I inhibitor) in combination with fluorouracil (thymidy | TOP1, TYMS | Phase 2 | Resectable Pancreatic Adenocarcinoma | Feb 2027 |
| Centre Hospitalier Universitaire Dijon | FOLFOXIRI Protocol (modified FOLFIRINOX) Combination chemotherapy: irinotecan (TOPO1 inhibitor) + oxaliplatin (TOPO2 inhibitor) + f | TOPO1, TOPO2, TYMS | Phase 2 | Locally Advanced or Metastatic Small Bowel Adenocarcinoma; Neuroendocrine Carcinoma | Feb 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | SOX S-1 and oxaliplatin combination chemotherapy | TYMS | Phase 2 | Gastric Cancer | Mar 2027 |
| Fudan University | TAS-102 Thymidylate synthase inhibitor; prodrug metabolized to FdUMP and FUTP | TYMS | Phase 2 | Metastatic Colorectal Cancer (CRC) | Apr 2027 |
| Zhen-Hai Lu | XELOX Oxaliplatin + capecitabine; platinum-based chemotherapy combined with fluoropyrimidine | TYMS | Phase 2 | Advanced Rectal Cancer | May 2027 |
| Memorial Sloan Kettering Cancer Center | floxuridine Thymidylate synthase inhibitor | TYMS | Phase 2 | Colorectal Cancer; Intrahepatic Cholangiocarcinoma | May 2027 |
| Lithuanian University of Health Sciences | FOLFOX4 Combination chemotherapy with oxaliplatin (platinum agent), 5-fluorouracil (thymidylate sy | DHFR, TYMS | Phase 2 | Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX | Jun 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | S-1 Fluoropyrimidine combination (5-FU prodrug with CDHP and OXO) | TYMS, DHFR | Phase 2 | Gastric Cancer | Jul 2027 |
| Peking University Cancer Hospital & Institute | tegafur, gimeracil and oteracil potassium (SOX) fluoropyrimidine-based regimen; thymidylate synthase inhibitor | TYMS | Phase 2 | Hepatoid Adenocarcinoma of Stomach | Sep 2027 |
| The First Affiliated Hospital with Nanjing Medical University | 5-FU/LV 5-fluorouracil with leucovorin potentiation (thymidylate synthase inhibitor) | TYMS | Phase 2 | Pancreatic Cancer | Sep 2027 |
| Qingdao Central Hospital | TAS-102 5-FU prodrug with thymidylate synthase and dihydrofolate reductase inhibition | TYMS, DHFR | Phase 2 | EFS | Dec 2027 |
| St. Olavs Hospital | FOLFOX Combination chemotherapy with oxaliplatin (platinum-based DNA alkylating agent), 5-fluorou | TYMS | Phase 2 | Tumor, Colorectal | Dec 2027 |
| Tianjin Medical University Cancer Institute and Hospital | 5-FU/LV Fluoropyrimidine antimetabolite with leucovorin potentiation | TYMS | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | Dec 2027 |
| Fudan University | FOLFOX Combination of 5-fluorouracil (thymidylate synthase inhibitor), leucovorin (folate cofacto | TYMS | Phase 2 | ctDNA | Dec 2027 |
| UMC Utrecht | FTD-TPI Thymidylate synthase inhibitor | TYMS | Phase 2 | Metastatic Colorectal Cancer | Jan 2028 |
| Michael J Cavnar, MD | Floxuridine Thymidylate synthase inhibitor | TYMS | Phase 2 | Colorectal Cancer Metastatic | Feb 2028 |
| Mayo Clinic | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 2 | Metastatic Salivary Gland Carcinoma | Feb 2028 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Tegafur Thymidylate synthase inhibitor (prodrug of 5-FU) | TYMS | Phase 2 | Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Mar 2028 |
| Fudan University | mFOLFIRINOX plus IMRT Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co | TOPO1, DPYD, TYMS, DHFR | Phase 2 | Pancreatic Adenocarcinoma; Pancreatic Cancer | Mar 2028 |
| Ciusss de L'Est de l'Île de Montréal | Modified early post-operative intraperitoneal chemotherapy (mEPIC) Intraperitoneal fluorouracil chemotherapy | TYMS | Phase 2 | Peritoneal Carcinomatosis | May 2028 |
| Dartmouth-Hitchcock Medical Center | modified FOLFIRINOX (mFOLFIRINOX) Combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; multi-targeted che | TYMS, DHFR | Phase 2 | Pancreas Adenocarcinoma | Jul 2028 |
| M.D. Anderson Cancer Center | Trifluridine and Tipiracil Hydrochloride Thymidylate synthase inhibitor with bioavailability enhancer | TYMS | Phase 2 | Refractory Colorectal Carcinoma | Aug 2028 |
| Erasmus Medical Center | Floxuridin Thymidylate synthase inhibitor (via fluorouracil metabolite) | TYMS | Phase 2 | Intrahepatic Bile Duct Cancer | Sep 2028 |
| University of Wisconsin, Madison | TAS102 Thymidylate synthase inhibitor and nucleoside analog | TYMS | Phase 2 | Metastatic Colorectal Cancer | Sep 2028 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Tegafur Antimetabolite (prodrug of fluorouracil) | TYMS, DHFR | Phase 2 | Immunotherapy | Sep 2028 |
| UNICANCER | Lonsurf (Trifluridine/tipiracil) Thymidylate synthase inhibitor and DHFR inhibitor combination; trifluridine is a nucleosid | TYMS, DHFR | Phase 2 | Metastatic Colorectal Cancer | Oct 2028 |
| The Methodist Hospital Research Institute | 5FU/LV 5-Fluorouracil (5FU) is a thymidylate synthase inhibitor; leucovorin (LV) enhances 5FU eff | TYMS | Phase 2 | Metastatic Colorectal Cancer (CRC) | Dec 2028 |
| Corewell Health West | Floxuridine Thymidylate synthase inhibitor | TYMS | Phase 2 | Pancreatic Adenocarcinoma | Dec 2028 |
| NRG Oncology | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 2 | Recurrent Non-Small Cell Lung Carcinoma | Dec 2028 |
| Centre Georges Francois Leclerc | FOLFIRINOX3 Combination chemotherapy: 5-FU (thymidylate synthase inhibitor), irinotecan (topoisomerase | TYMS, DHFR | Phase 2 | Metastatic Pancreatic Cancer | Jul 2029 |
| Duke University | FLOT 5-FU + Leucovorin + Oxaliplatin + Docetaxel (antimetabolite + folinic acid + platinum alky | TYMS, DHFR | Phase 2 | Esophageal Adenocarcinoma | Sep 2029 |
| Duke University | Modified-FOLFOX-6 5-FU + Leucovorin + Oxaliplatin (5-FU thymidylate synthase inhibitor + folinic acid + plat | TYMS, DHFR | Phase 2 | Esophageal Adenocarcinoma | Sep 2029 |
| Dominik Paul Modest | Trifluridine/Tipiracil Hydrochloride Thymidylate synthase inhibitor and thymidine phosphorylase inhibitor | TYMS | Phase 2 | Metastatic Colorectal Cancer | Dec 2029 |
| Ruijin Hospital | SOX S-1 (tegafur/gimeracil/oteracil) + oxaliplatin chemotherapy regimen | TYMS | Phase 2 | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | May 2030 |
| Oslo University Hospital | Floxuridine Thymidylate synthase inhibitor | TYMS | Phase 2 | Intrahepatic Cholangiocarcinoma | Jan 2031 |
| Ashish Shah | DB107-FC Flucytosine; prodrug converted by cytosine deaminase to fluorouracil | TYMS, DHFR | Phase 2 | High Grade Glioma | May 2034 |
| Sunnybrook Health Sciences Centre | Floxuridine Thymidylate synthase inhibitor | TYMS | Phase 2 | Colorectal Adenocarcinoma Metastatic in the Liver | Dec 2036 |
| Qilu Hospital of Shandong University | Raltitrexed Thymidylate synthase inhibitor | TYMS | Phase 2 | Intrahepatic Cholangiocarcinoma | – |
| University of California, Irvine | TAS-102 Thymidylate synthase inhibitor (trifluoridine); irinotecan topoisomerase I inhibitor combi | TYMS | Phase 1 | Colon Adenocarcinoma | Jan 2027 |
| Clinica Universidad de Navarra, Universidad de Navarra | TTFields Combination chemotherapy: folate antagonist (5-FU/leucovorin), topoisomerase I inhibitor ( | TYMS, DHFR | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Mar 2027 |
| National Cancer Institute (NCI) | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 1 | Epithelioid Mesothelioma; Biphasic Mesothelioma | Mar 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Raltitrexed-PIPAC Raltitrexed (thymidylate synthase inhibitor) delivered via pressurized intraperitoneal aer | TYMS | Phase 1 | Peritoneal Metastasis | Oct 2027 |
| National Health Research Institutes, Taiwan | Trifluridine/Tipiracil (LONSURF) Combination of nucleoside analog and thymidine phosphorylase inhibitor; inhibits thymidyla | TYMS | Phase 1 | Metastatic Gastric Adenocarcinoma | Dec 2027 |
| University of Colorado, Denver | NALIRIFOX Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil (thymidyla | TOPO1, TOPO2A, TYMS | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Jul 2028 |
| Roswell Park Cancer Institute | Trifluridine and Tipiracil Hydrochloride Nucleoside analog (thymidine derivative) and thymidine phosphorylase inhibitor; inhibits D | TYMS, PNP | Phase 1 | Advanced Malignant Solid Neoplasm | Sep 2028 |
| Institute of Cancer Research, United Kingdom | Idetrexed Folate receptor-targeted thymidylate synthase inhibitor | TYMS, FOLR1 | Phase 1 | High Grade Serous Ovarian Cancer | Dec 2029 |
Metastatic Colorectal Cancer (5) Colorectal Cancer (4) Colon Cancer (4) Gastric Cancer (3) Rectal Cancer (3) Pancreatic Adenocarcinoma (3) Intrahepatic Cholangiocarcinoma (3) High-risk Stage II Colorectal Cancer (3) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (2) Metastatic Colorectal Cancer (CRC) (2) Esophageal Adenocarcinoma (2) Intrahepatic Cholangiocarcinoma (Icc) (2)
small molecule (38), mixed (14), antibody (8), other (2)
Fudan University (6) Centre Hospitalier Universitaire Dijon (3) Duke University (3) Sixth Affiliated Hospital, Sun Yat-sen University (2) Ruijin Hospital (2) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) Qilu Hospital of Shandong University (2) Kyungpook National University Hospital (2) Chinese University of Hong Kong (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Lithuanian University of Health Sciences (1) The Methodist Hospital Research Institute (1) Michael J Cavnar, MD (1) The Netherlands Cancer Institute (1) Dartmouth-Hitchcock Medical Center (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) National Health Research Institutes, Taiwan (1) Shandong Cancer Hospital and Institute (1) Zhen-Hai Lu (1) Assistance Publique - Hôpitaux de Paris (1)
DHFR (26) TOPO1 (7) SLC22A16 (4) GART (3) TOPO2 (2) TOPO2A (2) DPYD (2) MTHFR (1) Tubulin (1) TP53 (1) RRM1 (1) OPRT (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.